ReviewMedical oncology (Northwood, London, England)2011
Adiponectin and breast cancer.
Review in Medical oncology (Northwood, London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis.International journal of epidemiology · 2014Pooled it
- The role of adiponectin in breast cancer: a meta-analysis.PloS one · 2013Pooled it
- Gene expression changes in adipose tissue with diet- and/or exercise-induced weight loss.Cancer prevention research (Philadelphia, Pa.) · 2013Trial
- Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012Trial
- Exploring the multifaceted role of obesity in breast cancer progression.Frontiers in cell and developmental biology · 2024Review
- Multidisciplinary Progress in Obesity Research.Genes · 2022Review
- A paradoxical role for sestrin 2 protein in tumor suppression and tumorigenesis.Cancer cell international · 2021Review
- Associations between ADIPOQ rs2241766 SNP and breast cancer risk: a systematic review and a meta-analysis.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2021Article
- Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis.Frontiers in oncology · 2021Review
- Interfering Role of ERα on Adiponectin Action in Breast Cancer.Frontiers in endocrinology · 2020Review
- Adiponectin, Obesity, and Cancer: Clash of the Bigwigs in Health and Disease.International journal of molecular sciences · 2019Review
- Dual-therapy strategy for modification of adiponectin receptor signaling in aging-associated chronic diseases.Drug discovery today · 2018Review
- Multifaceted Roles of Interleukin-6 in Adipocyte-Breast Cancer Cell Interaction.Translational oncology · 2018Review
- ADIPOQ/adiponectin induces cytotoxic autophagy in breast cancer cells through STK11/LKB1-mediated activation of the AMPK-ULK1 axis.Autophagy · 2017Article
- Impact of Weight Loss on Plasma Leptin and Adiponectin in Overweight-to-Obese Post Menopausal Breast Cancer Survivors.Nutrients · 2015Article
- Cross-Talk between Adiponectin and IGF-IR in Breast Cancer.Frontiers in oncology · 2015Review
- Leptin and adiponectin: emerging therapeutic targets in breast cancer.Journal of mammary gland biology and neoplasia · 2013Review
- Expression of epidermal growth factor, transforming growth factor-β1 and adiponectin in nipple aspirate fluid and plasma of pre and post-menopausal women.Biomarker research · 2013Article
- Adiponectin receptors form homomers and heteromers exhibiting distinct ligand binding and intracellular signaling properties.The Journal of biological chemistry · 2013Article
- Obesity and cholangiocarcinoma.World journal of gastroenterology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adiponectin, an adipose tissue-derived hormone, has been studied intensively for the past decade because of its anti-inflammatory, anti-atherogenic, and anti-diabetic properties. Recent advances suggest that adiponectin also plays an important role in the development and progression of various cancers, especially obesity-related cancers. In this review, the authors focus on the potential role of adiponectin in breast cancer, an obesity- and endocrine-associated tumor. Epidemiological studies have shown that plasma adiponectin level is a risk factor for breast cancer in post-menopausal women. Adiponectin and its receptors are expressed on both breast cancer line cells and tumor tissues. Furthermore, exogenous adiponectin has exhibited therapeutic potential in animal models. Underlying mechanisms include the inhibition of cell proliferation and promotion of apoptosis, the regulation of tumorigenic-related factors, and the suppression of angiogenesis. The signaling pathways linking adiponectin with tumorigenesis might provide potential drug targets for the future. However, more convincing evidence is needed to fully elucidate the exact role of adiponectin in breast cancer, since both its beneficial effects and possible mechanisms remain controversial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.